Event type
Lectures and seminars
StratNeuro lunch seminar November 2021

08-11-2021 12:00 pm - 1:00 pm Add to iCal
Location
Online via Zoom and Von Euler room (J3:06), BioClinicum, Solnavägen 30
Lead

Welcome to the StratNeuro seminar on the topic "Molecular/Cellular Pathophysiology of Parkinson's disease".

Content

Coffee and sandwich offered to up to 30 persons attending in-person.

Join the meeting via Zoom here.

Speakers

Speakers will be announced soon.

Contact

The Strategic Research Area Neuroscience (StratNeuro) | StratNeuro@ki.se

Event type
Lectures and seminars
Thomas Sakmar: "Uveal Melanoma: Case History of a Mutant GPCR – and Reflections on a Career in Science"

11-11-2021 9:00 am Add to iCal
Karolinska University Hospital, Solna
Location
Sune Bergströms aula (J3:07), Bioclinicum, entrance through Solnavägen 30
Lead

Honorary Doctor Thomas Sakmar, Visiting Professor of Molecular Biology and Biochemistry at the Department of Neurobiology, Care Sciences and Society (NVS) and active at the Rockefeller University, will give a talk on "Uveal Melanoma:Case History of a Mutant GPCR - and Reflections on a Career in Science.”

Coffee/Tea will be offered.

Event type
Lectures and seminars
Epidemiology Methods Series, IMM

25-11-2021 3:00 pm - 4:00 pm Add to iCal
Online
Location
Zoom
Lead

What is systematic and what is random error when it comes to bias analysis?

Content

Welcome to the Epidemiology Methods Series at the Institute of Environmental Medicine, Karolinska Institutet.

We are pleased to be joined for an online Zoom webinar by Issa Dahabreh from the Harvard T.H. Chan School of Public Health to give a talk titled “Randomized trials and their observational emulations: benchmarking and joint analysis”

Abstract: We consider a randomized trial and an observational analysis designed to emulate the trial as closely as possible, to benchmark the observational analysis estimates against those from the trial. We show that benchmarking relies on an exchangeability condition between the populations underlying the trial and its emulation. When this exchangeability condition holds, and the usual conditions needed for estimates from the trial and the emulation to have a causal interpretation also hold, we show that joint analysis of the trial and the emulation is possible.

Please register for the webinar at: https://survey.ki.se/epimethodsseries_nov21

Links for the event will be sent out the day before.

Flyer

 

Contact

Event type
Lectures and seminars
Karolinska Immunology Seminar Series (KiSS) 9

28-10-2021 3:00 pm Add to iCal
Karolinska University Hospital, Solna
Location
Zoom based, lecture halls J3:04 and J3:07 at the ground hall Bioclinicum.
Lead

The aim of Karolinska Immunology Seminar Series (KiSS) is to create an event with top speakers from all over the world that brings together the immunological community of Karolinska Institutet and Karolinska University Hospital. We aim to cover a diverse spectrum of immunological topics while at the same time inviting outstanding speakers whose work is of general interest for everyone who wants to follow current trends in immunology.

Content

We plan that, if epidemiological situation permits, most of the seminars (with the exception of the ones marked as webinars below) will take place in hybrid mode: through zoom and in lecture halls J3:04 and J3:07 at the ground hall Bioclinicum. Please follow the emails (sent through KiiM list) to stay tuned about the exact format of events and possible changes. Zoom links will be sent through this mailing list as well (contact one of the organizers a day or two before the seminar if you did not receive the link). Note that webinar version is open only to researchers based in Stockholm.

The seminars are supported by Allergy, Immunology and Inflammation PhD program.

All seminars are on Thursdays, 15:00-16:00

Karolinska Immunology Seminar Series (KiSS):

Contact: taras.kreslavskiy@ki.se,(Solna) carmen.gerlach@ki.se (Solna) isabelle.magalhaes@ki.se (Huddinge)

Thursday, 2021-10-28, 15:00-16:00

Meinrad Busslinger (IMP, Austria)
Role of Pax5 in B cell immunity and disease

Event type
Lectures and seminars
ISP seminar - Jutta Jalkanen

09-11-2021 10:00 am - 11:00 am Add to iCal
Campus Flemingsberg
Location
Room DNA 5105, in Neo, Blickagången 16, Flemingsberg
Lead

Welcome to the ISP seminar of a newly appointed doctoral student at MedH, Jutta Jalkanen with the title "Determinants of adipocyte lipid turnover in metabolic disease".

Contact

Event type
Lectures and seminars
Sfo Epi Seminar in Biostatistics: Development of a multiparametric MR classifier for prostate cancer

19-11-2021 4:00 pm - 5:00 pm Add to iCal
Campus Solna
Location
https://ki-se.zoom.us/j/62697743133
Lead

Welcome to attend the SfoEpi Seminar Series in Biostatistics!
Title: Development of a multiparametric MR classifier for prostate cancer

Content

Speaker

Joseph Koopmeiners, Mayo Professor and Head, Division of Biostatistics, School of Public Health, University of Minnesota

Abstract

Multiparametric magnetic resonance imaging (mpMRI) represents a powerful tool for developing a non-invasive, user-independent tool for the detection of prostate cancer. Previously, our group showed that a voxel-wise classifier that combined quantitative mpMRI parameters from multiple modalities resulted in better classification of prostate cancer than any single parameter, alone. While these results are promising, there are several unique features of the mpMRI data that can be leveraged to improve classification accuracy. First, the prostate has a unique anatomical structure, whereby it can be segmented into multiple zones, with the largest being the central gland and peripheral zone. Both the mpMRI parameters and the prevalence of cancer are associated with region, and leveraging this information can potentially improve classification. Second, there is substantial spatial correlation in both the mpMRI parameters and the voxel-wise cancer status, but developing a classifier that leverages this information is challenging due to the high dimensionality of the data. Finally, while data are available on the voxel-level, voxel-wise predictions must be translated into contiguous lesions for clinical use in imaging-guided biopsy and focal therapy. In this talk, I will discuss the development of quantitative methods that allow us to leverage the unique features of our data to improve prostate cancer classification and localization. First, I will discuss the development of a voxel-wise prostate cancer classifier that accounts for the anatomical structure of the prostate and spatial correlation in the data. I will then discuss a novel Bayesian functional spatial partitioning algorithm that uses functional estimation tools to estimate smooth boundary curves of arbitrary shape. I will illustrate our methods through an application to a data set consisting of mpMRI of the prostate co-registered to pathology.  

If you have any questions, please contact Erin Gabriel at Erin.Gabriel@ki.se

Zoom: https://ki-se.zoom.us/j/62697743133

Contact

Event type
Lectures and seminars
Drug Discovery Seminar: "PROTAC Degraders: From Fundamental Chemical Biology to Translation and Entrepreneurship"

12-11-2021 2:00 pm - 3:00 pm Add to iCal
Other
Location
Navet, BMC Uppsala, Husargatan 3, Uppsala and Zoom
Lead

Welcome to join this Drug Discovery Seminar with Alessio Ciulli from University of Dundee. Hosted by the Drug Discovery and Development Platform.

Content

Speaker

Alessio Ciulli, University of Dundee

Alessio Ciulli holds the Personal Chair of Chemical Structural Biology at the School of Life Sciences, University of Dundee. He is also the Director of the newly announced Dundee’s Centre for Targeted Protein Degradation (CeTPD). Dr Ciulli’s laboratory has made important contributions to selective chemical intervention on protein-protein interactions targets and to the development of proteolysis-targeting chimeric molecules (PROTACs) as a viable strategy for targeted protein degradation. Amongst his most significant discoveries are the fragment-based design of ligands for the E3 ligase von Hippel-Lindau (VHL), and their use to design one of the first VHL-based PROTACs: the BET degrader MZ1.

Dr Ciulli’s Lab later illuminated fundamental insights into PROTACs’ mechanism of action, solving the first crystal structure of a PROTAC ternary complex. Dr. Ciulli is the scientific founder of Amphista therapeutics, a company that develops new protein degradation platforms. Before joining Dundee, Dr Ciulli was a group leader at the University of Cambridge, where he previously earned his PhD degree. Amongst his honours are the EFMC Prize for Young Medicinal Chemist in Academia, the RSC Capps Green Zomaya Award in medicinal computational chemistry, and election as Fellow of the Royal Society of Chemistry.

PROTAC Degraders: From Fundamental Chemical Biology to Translation and Entrepreneurship

Proteolysis-targeting chimeras (PROTACs) are a new class of chemical tools and drugs that target disease-causing proteins for degradation. They are designed to harness the cell’s natural disposal system (the ubiquitin-proteasome) to specifically remove proteins. A PROTAC is a two-headed (i.e. bifunctional) molecule where one end binds an enzyme (an E3 ubiquitin ligase) and the other binds the target protein, bringing the two proteins into close proximity as a ternary complex. The ligase is then able to label the target protein for ubiquitination and so degradation by the cell’s disposal system. Whereas conventional drugs only inhibit disease proteins by binding and locking up their most important functional parts for the duration of the drug’s action, PROTACs can bind at any positions and rapidly cause the disease protein’s permanent and long-lasting destruction. Due to this revolutionary mode of action, PROTACs can attack targets previously thought ‘undruggable’. 

In my lecture, I will outline some key discoveries from my laboratory that have advanced the chemical structural biology of PROTACs, and are providing fundamental insights into our understanding of their molecular recognition, mechanism of action and drug design. I will also offer insights from our efforts to translate this fundamental science into molecular therapeutics to benefit patients, via both partnerships with big pharma and formation of company spin-outs. Finally I will highlight the vision and mission of our recently announced new Centre for Targeted Protein Degradation at Dundee.

Register

Register to the seminar

SciLifeLab Drug Discovery Seminars

SciLifeLab Drug Discovery Seminars, hosted by the DDD platform, is a series of educational lectures about recent developments, technologies, and trends in drug discovery and development that aims to enlighten, and spark a discussion, within the Swedish drug discovery community.

Contact

Event type
Lectures and seminars
Drug Discovery Seminar: "How protein degradation led to faculty entrepreneurship at Yale: A personal Perspective"

10-11-2021 2:00 pm - 3:00 pm Add to iCal
Campus Solna
Location
Air&Fire, SciLifeLab Solna, Tomtebodavägen 23 A and Zoom
Lead

Welcome to join this Drug Discovery Seminar with Craig Crews from Yale University. Hosted by the Drug Discovery and Development Platform.

Content

Speaker

Craig Crews, Yale University, Scheele Prize winner 2021 from the Swedish Pharmaceutical Society

Crews is the John C. Malone Professor of Molecular, Cellular and Developmental Biology and holds joint appointments in the departments of Chemistry and Pharmacology at Yale University. He graduated from the U.Virginia with a B.A. in Chemistry and received his Ph.D. from Harvard University in Biochemistry. Dr. Crews has a foothold in both the academic and biotech arenas; on the faculty at Yale since 1995, his laboratory has pioneered the use of small molecules to control intracellular protein levels.

In 2003, he co-founded Proteolix, Inc., whose proteasome inhibitor, Kyprolis™ received FDA approval for the treatment of multiple myeloma. Since Proteolix’s purchase by Onyx Pharmaceuticals in 2009, Dr. Crews has focused on a new drug development technology, which served as the founding intellectual property for his latest New Haven-based biotech venture, Arvinas, Inc.

Currently, Dr. Crews serves on several editorial boards and was Editor of Cell Chemical Biology (2008-2018). In addition, he has received numerous awards and honors, including the 2013 CURE Entrepreneur of the Year Award, 2014 Ehrlich Award for Medicinal Chemistry, 2015 Yale Cancer Center Translational Research Prize, a NIH R35 Outstanding Investigator Award (2015), the AACR Award for Chemistry in Cancer Research (2017), Khorana Prize from the Royal Society of Chemistry (2018), Pierre Fabre Award for Therapeutic Innovation (2018), the Pharmacia-ASPET Award for Experimental Therapeutics (2019), the Heinrich Wieland Prize (2020) and the Scheele Prize (2021). In 2019, he was named an American Cancer Society Professor.

How protein degradation led to faculty entrepreneurship at Yale: A personal Perspective

Prof. Crews is the 2021 recipient of the Scheele prize from the Swedish Pharmaceutical Society for his seminal work on protein degradation. In this talk Prof. Crews will discuss his efforts to translate research from his lab into new biopharma ventures. To date, these entrepreneurial  efforts have resulted in a FDA approved drug (Kyprolis) and a new therapeutic modality (PROTACs).  While each of his four companies has been launched based on different science, they have all followed a similar business model and Prof. Crews will discuss efforts at Yale to ’systematize’ faculty entrepreneurism via a core ‘biotech accelerator’ facility.

Register

Register to the seminar

SciLifeLab Drug Discovery Seminars

SciLifeLab Drug Discovery Seminars, hosted by the DDD platform, is a series of educational lectures about recent developments, technologies, and trends in drug discovery and development that aims to enlighten, and spark a discussion, within the Swedish drug discovery community.

Contact

Event type
Lectures and seminars
Drug Discovery Seminar: "Targeting the oncogenic TGFβ signaling pathway in cancer to inhibit invasion and metastasis"

28-10-2021 1:00 pm - 2:00 pm Add to iCal
Campus Solna
Location
Gamma 7, SciLifeLab, Tomtebodavägen 23a and Zoom
Lead

Welcome to join this Drug Discovery Seminar with Maréne Landström from Umeå University. Hosted by the Drug Discovery and Development Platform.

Content

Speaker

Maréne Landström, Umeå University

Maréne Landström is a professor in Pathology at Department of Medical Biosciences, Umeå University, Sweden. She has made her postdoctoral training at the Ludwig Institute of Cancer Research, Uppsala Branch and have also been a group leader at Department of Immunology, Genetics and Pathology, Uppsala University before taking on her current position.

Targeting the oncogenic TGFβ signaling pathway in cancer to inhibit invasion and metastasis

Transforming growth factor beta (TGFb) is frequently overexpressed in several forms of cancer including prostate cancer and this has been shown to correlate with poor prognosis. TGFb is transducing its canonical and non-canonical signals via its transmembrane TGFb Type II and Type I receptors (TbRII/TbRI) which are serine-threonine kinases. We have found that the TbRI undergoes proteolytic cleavage in cancer cells in a manner dependent on the ubiquitin-ligase tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6). The intracellular domain of TbRI (TbRI-ICD) is released from the cell membrane, soluble and is transported to the nucleus in some specific forms of cancer to promote expression of genes causing invasion and metastatic growth. In collaboration with SciLifeLab DDD we have generated potential therapeutic antibodies to target this pathway which we are investigating the function of, in our established preclinical models for prostate cancer.

Register

Register to the seminar

SciLifeLab Drug Discovery Seminars

SciLifeLab Drug Discovery Seminars, hosted by the DDD platform, is a series of educational lectures about recent developments, technologies, and trends in drug discovery and development that aims to enlighten, and spark a discussion, within the Swedish drug discovery community.

Contact

Event type
Lectures and seminars
CMB Guest Seminar: Professor David M. Gilbert

22-11-2021 10:00 am - 11:00 am Add to iCal
Campus Solna
Location
Eva & Georg Klein, Biomedicum, Solnavägen 9
Lead

Regulation of Replication Timing and Chromosome Architecture.
10:00 in Eva & Georg Klein.

Content

Guest: Professor David M. Gilbert, San Diego Biomedical Research Institute, San Diego, CA, USA. 
When: November 22nd, 10.00-11.00
Where: Eva & Georg Klein in Biomedicum
Title: “Regulation of Replication Timing and Chromosome Architecture

Dr. Gilbert’s work focuses on the regulation of DNA replication and the re-modeling of chromosome structure and transcription during differentiation of human and mouse embryonic stem cells. He recently discovered Early Replication Control Elements (ERCEs) that co-regulate replication, transcription and chromatin architecture of replication domains and that the temporal order of replication is necessary to maintain the global epigenome.

Selected publications:

Identifying cis Elements for Spatiotemporal Control of Mammalian DNA Replication.
Sima J, Chakraborty A, Dileep V, Michalski M, Klein KN, Holcomb NP, Turner JL, Paulsen MT, Rivera-Mulia JC, Trevilla-Garcia C, Bartlett DA, Zhao PA, Washburn BK, Nora EP, Kraft K, Mundlos S, Bruneau BG, Ljungman M, Fraser P, Ay F, Gilbert DM
Cell 2019 02;176(4):816-830.e18

Replication timing maintains the global epigenetic state in human cells.
Klein KN, Zhao PA, Lyu X, Sasaki T, Bartlett DA, Singh AM, Tasan I, Zhang M, Watts LP, Hiraga SI, Natsume T, Zhou X, Baslan T, Leung D, Kanemaki MT, Donaldson AD, Zhao H, Dalton S, Corces VG, Gilbert DM
Science 2021 04;372(6540):371-378

Contact

Subscribe to Lectures and seminars